ANTICANCER AGENTS FROM UNIQUE NATURAL PRODUCTS SOURCES

来自独特天然产品来源的抗癌剂

• 批准号: 2769794
• 负责人: Chris M. Ireland
• 金额: $ 48.38万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-08 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2769794
• 关键词: antineoplastics; aquatic organism; biological products; cooperative study; drug screening /evaluation; marine biology; neoplasm /cancer pharmacology

The underlying theme of this program is to integrate discovery of novel biologically active natural products from organisms that inhabit unique ecological niches with mechanism-directed cancer biology. The overall goal is the identification of clinically useful drugs that target human solid tumor diseases and related infections caused by immune deficiency. The PI, Dr. Ireland will be responsible for administration of the program, including financial management, orchestrating communication between the groups and dissemination of data, tracking of priority leads and arranging meetings with NIH officials. Dr. Ireland will also oversee a natural products subprogram for studies of the chemistry of marine invertebrate animals and associated microorganisms. Dr. Kramer will be responsible for the drug development aspect of this program. This will include initial testing of samples supplied by the natural products groups in Cyanamid's Oncology Drug Screen (CODS), mechanism of action studies, animal toxicology and in vivo antitumor studies in animal models. Dr. Kramer will also oversee testing of samples in immune stimulation assays. Dr. Maiese will oversee a subprogram for studies of marine micro- organisms. Particular emphasis will be placed on micro-organisms obtained from specific environments. Dr. Maiese's group will be responsible for isolation, taxonomic identification and fermentation of subject micro-organisms. Dr. Clardy will oversee a natural products subprogram for studies of novel endophytic fungi and a smaller effort on the characterization of leads by X-ray diffraction. Dr. Andersen will oversee a natural products subprogram for studies of marine invertebrate animals and associated microorganisms.

该计划的基本主题是整合发现 来自栖息生物的新型生物活性天然产物 具有机制导向的癌症生物学的独特生态位。这 总体目标是鉴定临床上有用的药物 针对人类实体瘤疾病及相关感染引起的 免疫缺陷。 PI，爱尔兰博士将负责 该计划的管理，包括财务管理， 协调团体之间的沟通和传播 数据、跟踪优先线索并安排与 NIH 的会议 官员。爱尔兰博士还将监督天然产品子计划 用于研究海洋无脊椎动物的化学和 相关微生物。 Kramer 博士将负责该药物 该计划的开发方面。这将包括初步测试 Cyanamid 天然产物小组提供的样品 肿瘤药物筛选 (CODS)、作用机制研究、动物 动物模型中的毒理学和体内抗肿瘤研究。克莱默博士 还将监督免疫刺激试验中样品的测试。博士。 Maiese 将监督海洋微生物研究的子计划 有机体。将特别强调微生物 从特定环境中获得。 Maiese 博士的小组将 负责分离、分类鉴定和发酵 主题微生物。克拉迪博士将监督天然产品 研究新型内生真菌的子计划和较小的努力 通过 X 射线衍射表征铅。安徒生博士 将监督海洋研究的天然产品子计划 无脊椎动物和相关微生物。